Russell Investments Group Ltd. increased its stake in Axonics, Inc. (NASDAQ:AXNX - Free Report) by 1,144,500.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,568 shares of the company's stock after acquiring an additional 91,560 shares during the period. Russell Investments Group Ltd. owned approximately 0.18% of Axonics worth $5,698,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. Headlands Technologies LLC acquired a new stake in Axonics during the fourth quarter valued at $53,000. RiverPark Advisors LLC acquired a new stake in Axonics in the third quarter valued at approximately $58,000. C M Bidwell & Associates Ltd. increased its position in Axonics by 108.2% during the third quarter. C M Bidwell & Associates Ltd. now owns 1,270 shares of the company's stock worth $71,000 after buying an additional 660 shares during the last quarter. Sentry Investment Management LLC bought a new stake in shares of Axonics during the 4th quarter worth about $125,000. Finally, Covestor Ltd raised its stake in shares of Axonics by 40.8% in the 3rd quarter. Covestor Ltd now owns 3,143 shares of the company's stock valued at $176,000 after acquiring an additional 911 shares in the last quarter. 99.48% of the stock is currently owned by institutional investors and hedge funds.
Axonics Stock Up 0.0 %
Shares of AXNX stock traded up $0.03 on Friday, reaching $67.43. The company's stock had a trading volume of 233,015 shares, compared to its average volume of 1,160,894. Axonics, Inc. has a 12-month low of $47.59 and a 12-month high of $69.68. The company has a market capitalization of $3.44 billion, a P/E ratio of -210.63 and a beta of 0.60. The stock's 50 day simple moving average is $67.72 and its 200-day simple moving average is $63.59.
Axonics (NASDAQ:AXNX - Get Free Report) last posted its quarterly earnings data on Tuesday, April 30th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.32). Axonics had a negative net margin of 4.12% and a negative return on equity of 2.58%. The company had revenue of $91.41 million for the quarter, compared to analysts' expectations of $89.79 million. During the same quarter last year, the business posted ($0.19) EPS. The business's quarterly revenue was up 29.4% compared to the same quarter last year. Research analysts expect that Axonics, Inc. will post 0.27 EPS for the current year.
Analyst Ratings Changes
AXNX has been the subject of a number of research analyst reports. SVB Leerink reissued a "market perform" rating and set a $71.00 target price on shares of Axonics in a research report on Friday, January 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Axonics in a research report on Monday. Royal Bank of Canada reissued a "sector perform" rating and issued a $71.00 price target on shares of Axonics in a report on Thursday, February 29th. Truist Financial reaffirmed a "hold" rating and set a $71.00 price objective (down previously from $73.00) on shares of Axonics in a research report on Friday, January 12th. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $71.00 target price (down from $75.00) on shares of Axonics in a research report on Friday, January 12th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $70.73.
View Our Latest Report on AXNX
Axonics Company Profile
(
Free Report)
Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.
Read More
Before you consider Axonics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axonics wasn't on the list.
While Axonics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
